Business
Universal Health Services operates acute-care hospitals and behavioral-health facilities.
Universal Health Services: Revenue grew 9.7% to $17.365B from $15.828B. Net income grew 30.4% to $1.489B from $1.142B. Free cash flow declined 24.4% to $849.245M from $1.123B. Operating margin expanded 85 bps to 11.48%. Universal Health Services's annual comparison also shows free cash flow declined despite revenue growth.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 9.7%OK
- Profitability — Net income grew 30.4% to $1.489B from $1.142BOK
- Cash flow — Free cash flow declined 24.4% to $849.245M from $1.123BWatch
- Margins — Operating margin expanded 85 bps to 11.48%OK
- Accounting — No overriding statistical warningNote
- Insiders — 0 purchases and 4 salesNote
Where the revenue comes from
Fiscal 2025, as UNIVERSAL HEALTH SERVICES INC reports it. History and quarterly detail are in the app.
- Managed Care$4.9B
- Medicaid$2.7B
- Managed Medicaid$2.5B
- Managed Medicare$2.1B
- Health Care$1.9B
Leadership changes
From UNIVERSAL HEALTH SERVICES INC's own filings, the day they're filed.
- Marc D. Miller · departureeff. 2025-03-19
- Alan B. Miller · departureeff. 2025-03-19
- Marc D. Miller · CEO · departure
Latest filings
- 8-K · Company announcement2026-08-21
- 8-K · Company announcement2026-08-17
- 8-K · Company announcement2026-08-13
- 10-Q · Quarterly report2026-08-07
- 8-K · Company announcement2026-07-28
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about UNIVERSAL HEALTH SERVICES INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.